Contact | Print version | PDF version | Send article | RSS feed

Myriad Genetics' Lead Drug Candidate Accepting Enrollment for a Phase 3 Clinical Trial

27 May 2005 - Myriad Genetics' lead drug candidate, FLURIZAN(TM), is currently accepting enrollment for a Phase 3 clinical trial in Alzheimer's disease. This compound is also being studied in a Phase 2b clinical trial for prostate cancer therapy. Myriad has a full pipeline of preclinical drug candidates in development and recently started Phase I human clinical trials for two additional cancer drugs, MPC-6827 and MPC-2130.